Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

ADMA Fast ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:Asymmetric Dimethylarginine
Please select your region to see available products and prices.
Cat. No. Size Price


REA212/96R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA, Immobilized antigen

Applications

Serum, Plasma-EDTA

Sample Requirements

20 µl patient serum or plasma

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0.2 µmol/l – 3.0 µmol/l

Limit of Detection

0.03 μmol/l

Intra-assay (Within-Run)

4.9 – 5.4 %

Inter-assay (Run-to-Run)

4.3 – 9.6 %

Summary

Research topic

Blood pressure regulation and NO metabolism, Cardiovascular disease

Summary

The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine. NOS activity can be downregulated by ADMA, an endogenous inhibitor of NOS. Elevated ADMA levels in plasma have been found in clinical studies including patients with hypercholeste­rolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders. ADMA may have diagnostic relevance as a novel cardiovascular risk marker.

References to Summary

References to ADMA

  • Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003 Oct 1;59 (4):824-33
  • Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003 Nov;24 (21):1912-9
  • Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr. 2003 Feb;22 (1):23-30
  • Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003 May 3;361 (9368):1511-7
  • Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002 Mar 20;287 (11):1420-6
  • Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, Maas R, Boeger R, Zoccali C. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J Hypertens. 2005 Oct;23 (10):1825-30
  • Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, Maas R, Boeger R, Zoccali C. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J Hypertens. 2005 Oct;23 (10):1825-30
  • Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992 Mar 7;339 (8793):572-5
  • Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001 Dec 22-29;358 (9299):2113-7
Related Products Documents